Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Roche’s Gazyvaro approved in Europe for follicular lymphoma

Roche’s Gazyvaro approved in Europe for follicular lymphoma

16th June 2016

Roche has announced that its cancer drug Gazyvaro has been approved in a new indication by the European Commission.

The drug has been ratified for use in combination with bendamustine chemotherapy, followed by Gazyvaro maintenance, in people with follicular lymphoma who did not respond or who progressed during or up to six months after treatment with MabThera or a MabThera-containing regimen.

This approval was based on positive data from a phase III clinical trial and represents the second approved indication for the drug in Europe. It is already available for use in combination with chlorambucil for people with previously untreated chronic lymphocytic leukaemia who cannot benefit from full-dose fludarabine-based therapy.

Dr Sandra Horning, chief medical officer and head of global product development at Roche, said: "For those who fail to achieve durable disease control with MabThera-based treatment, Gazyvaro plus bendamustine is an important new treatment option that has been shown to reduce the risk of disease progression or death by more than half."

The drug was approved in this indication by the US Food and Drug Administration earlier this year. In the US, it is marketed under the brand name Gazyva.ADNFCR-8000103-ID-801820309-ADNFCR

We have hundreds of jobs available across the Healthcare industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips and straight to your inbox.